Hyperion signs deal with Ucyclyd to acquire adjunctive therapy rights

The terms of the deal have not been disclosed.

Hyperion also entered into an amended and restated collaboration with Ucyclyd according to which Hyperion retains an option to acquire worldwide rights for BUPHENYL and AMMONUL.

Ravicti (glycerol phenylbutyrate) is an investigational drug formerly known as HPN-100 and a pre-pro-drug of phenylacetic acid, the active moiety of BUPHENYL.

BUPHENYL is FDA-approved adjunctive therapy for the chronic management of patients with urea cycle disorders due to deficiencies in carbamylphosphate synthetase (CPS), ornithine transcarbamylase (OTC), and argininosuccinic acid synthetase (AS).